Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Mirdametinib
2. Pd 0325901
3. Pd 325901
4. Pd-0325901
5. Pd-325901
6. Pd0325901
7. Pd325901
1. 391210-10-9
2. Pd0325901
3. Pd 0325901
4. Pd-0325901
5. Mirdametinib
6. (r)-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide
7. Pd-325901
8. (r)-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide
9. Pd 325901
10. Mirdametinib [usan]
11. Pd325901
12. 86k0j5ak6m
13. Chembl507361
14. Chebi:88249
15. Pd 901
16. N-{[(2r)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
17. Mirdametinib (usan)
18. Ncgc00189075-01
19. Pd 03525901
20. N-((r)-2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide
21. N-[((r)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
22. N-[(2r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide
23. 391209-97-5
24. Unii-86k0j5ak6m
25. N-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide
26. 4bm
27. N-(((r)-2,3-dihydroxypropyl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide
28. N-((2r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-benzamide
29. Mirdametinib [inn]
30. Dsstox_cid_24024
31. Dsstox_rid_80100
32. Dsstox_gsid_44024
33. Mirdametinib [who-dd]
34. Pd0325901(mirdametinib)
35. Schembl172904
36. Gtpl7935
37. Dtxsid0044024
38. Ex-a102
39. Bcpp000126
40. Bdbm104963
41. Hms3648a14
42. Amy36437
43. Zinc3938683
44. Tox21_113364
45. Mfcd09909925
46. Nsc755770
47. Nsc800840
48. S1036
49. Who 11299
50. Akos015855518
51. Bcp9001057
52. Ccg-221316
53. Cs-0062
54. Db07101
55. Ex-8602
56. Nsc-755770
57. Nsc-800840
58. Ncgc00381744-09
59. Hy-10254
60. Us8575391, Q
61. Bb 0261791
62. Cas-391210-10-9
63. Sw218101-2
64. D11675
65. Pd-0325901,pd325901
66. Pd 0325901, >=98% (hplc)
67. Pd0325901 (pd325901)
68. Sr-01000946344
69. J-502503
70. Sr-01000946344-1
71. Brd-k49865102-001-01-9
72. Q27088255
73. Insolution Mek1/2 Inhibitor Iii, Pd0325901 - Cas 391210-10-9
74. Benzamide,n-[(2r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-
75. N-((r)-2,3-dihydroxy[propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide
76. N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide
77. N-[(2r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]- Benzamide
78. N-[(2r)-2,3-dihydroxypropoxy]-3,4-difluoro-2[(2-fluoro-4-iodophenyl)amino]-benzamide
79. (-)-n-(((r)-2,3-dihydroxypropyl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide
80. N-(((r)-2,3-dihydroxypropyl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide N-((2r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
Molecular Weight | 482.19 g/mol |
---|---|
Molecular Formula | C16H14F3IN2O4 |
XLogP3 | 3 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 7 |
Exact Mass | 481.99504 g/mol |
Monoisotopic Mass | 481.99504 g/mol |
Topological Polar Surface Area | 90.8 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 465 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Mirdametinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mirdametinib, including repackagers and relabelers. The FDA regulates Mirdametinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mirdametinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Mirdametinib supplier is an individual or a company that provides Mirdametinib active pharmaceutical ingredient (API) or Mirdametinib finished formulations upon request. The Mirdametinib suppliers may include Mirdametinib API manufacturers, exporters, distributors and traders.
Mirdametinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mirdametinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mirdametinib GMP manufacturer or Mirdametinib GMP API supplier for your needs.
A Mirdametinib CoA (Certificate of Analysis) is a formal document that attests to Mirdametinib's compliance with Mirdametinib specifications and serves as a tool for batch-level quality control.
Mirdametinib CoA mostly includes findings from lab analyses of a specific batch. For each Mirdametinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mirdametinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Mirdametinib EP), Mirdametinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mirdametinib USP).
LOOKING FOR A SUPPLIER?